Small Animal Imaging Core Facility The goal of the Small Animal Imaging (SAI) core is to provide advanced animal imaging services, including imaging acquisition and image analysis tools that will facilitate cancer research at UNC and beyond. The imaging ability provided by the core allowed sophisticated monitoring of animal models, especially for studies focusing on cancer etiology and molecular therapeutics. The SAI core currently houses 10 imaging devices, including two 3T Siemens MR scanners, a 9.4T Bruker small animal MR scanner, a GE Explore animal PET/CT scanner, a UNC-designed high resolution SPECT scanner, a high resolution microCT for specimens (SCANCO), a high frequency ultrasound system (VisualSonics), and three IVIS optical imaging systems with capability for both bioluminescence and fluorescence imaging. Three additional imaging devices will be added to the SAI core in 2010: a GE SPECT/CT, a Fluorescence Molecular Tomography system, and a novel carbon nanotube-based CT. The SAI core currently supports 54 research projects. The SAI core requests $115,958 in CCSG funds, representing 12% its operating costs;63% of the core's use is allocated to Cancer Center members. The increase in funding is requested to support the additional personnel and service contracts for new imaging equipment. For the next funding cycle, the SAI core proposes two major goals: expanding imaging, education and training services and developing multimodality imaging technology and analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-35
Application #
8340291
Study Section
Subcommittee G - Education (NCI)
Project Start
2011-05-23
Project End
2015-11-30
Budget Start
2011-05-23
Budget End
2011-11-30
Support Year
35
Fiscal Year
2011
Total Cost
$224,344
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Zhang, Cun-Jin; Wang, Chenhui; Jiang, Meiling et al. (2018) Act1 is a negative regulator in T and B cells via direct inhibition of STAT3. Nat Commun 9:2745
Anderson, Chelsea; Engel, Stephanie M; Anders, Carey K et al. (2018) Live birth outcomes after adolescent and young adult breast cancer. Int J Cancer 142:1994-2002
Gralinski, Lisa E; Sheahan, Timothy P; Morrison, Thomas E et al. (2018) Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. MBio 9:

Showing the most recent 10 out of 1525 publications